Second Internet medical stock, Wei Yi booking?
In the past two months, the news about Wei Yi’s IPO has been more intensive and specific.
On March 27, Reuters quoted a source who reported that Weiyi has selected CMB International, Credit Suisse, and JP Morgan Chase as sponsors to prepare for about $ 1 billion (about $ 7.8 billion) in Hong Kong in the second half of this year. Hong Kong dollar). In this regard, micro-medicine expressed “no comment”.
This is the second time Reuters has reported on Weiyi ’s listing plan this month. Earlier, on February 28, Bloomberg said that Weiyi will hire a new CFO to lead the Hong Kong IPO. The next day, Weiyi issued a personnel appointment email to all employees, stating that Cai Qiang, the former chief executive of AIA Group, will officially serve as vice chairman and CFO of the board of Weiyi Group on April 1.
Before that, the listing of Weiyi only appeared in the senior management of the group. In May 2018, when Weiyi completed a $ 500 million Pro-IPO financing at a valuation of $ 5.5 billion, it announced that it plans to list its three businesses, namely micro-medical, micro-pharmaceutical and micro-medical insurance, as a whole in Hong Kong at the end of the year, and said The micro-medical insurance business will be independently listed on A shares. However, due to the delay in the implementation of its listing plan and the launch of the science and technology board, the topic surrounding the listing of Weiyi is shelving and diversion.
In June 2019, Liao Jieyuan, Chairman and CEO of Weiyi, said that Weiyi’s main IPO plan in Hong Kong has not changed.
Compared to the initial announcement of Weiyi’s listing plan in 2018, both the capital market and the user group now have a deeper understanding and broader recognition of Internet healthcare.
On the one hand, Ping An Good Doctor, who settled in Hong Kong stocks in 2018, played the role of a capital pathfinder in the Internet medical industry. Its stock price broke from two days after listing to a cut, and then began to fluctuate in the second half of 2019 Although the company has not been profitable so far, the capital market has revealed its optimistic attitude towards its future value. This is a reference for the latecomer Wei Yi.
On the other hand, after the new crown epidemic this year, online medical needs such as online consultation and medical e-commerce have been stimulated. Analysys Qianfan monitoring data shows that during the Spring Festival of 2020, the daily peak of the independent app in the field of online medical online consultation reached 6.712 million, with the largest increase close to 1.6 million. Wei Yi launched an online platform for treating new coronavirus infections, which helped facilitate 1.4 million consultations with doctors in a month.
Science Industry Research Center released a report showing that in 2020,Under the influence, it is expected that the scale of China’s online medical market will grow at more than 45%, and from 2011 to 2018, the average annual compound growth rate of China’s online medical market is 36.1%.
Under multiple favorable factors, Weiyi will accelerate its entry into the capital market in 2020.